Lista de obras - Ashley M. Hopkins - Dominio Público Uruguay

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift

artículo científico publicado en 2023

Author's Reply

Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors

scientific article published on 01 August 2019

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide

article

Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

artículo científico publicado en 2020

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability

artículo científico publicado en 2018

Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab

scientific article published on 01 December 2019

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data

scientific article published on 28 February 2019

Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients

scientific article published on 09 August 2019

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials

artículo científico publicado en 2019

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis

artículo científico publicado en 2015

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity

artículo científico publicado en 2019

Individualization of leflunomide dosing in rheumatoid arthritis patients

artículo científico publicado en 2014

Interactive Pharmacometric Applications Using R and the Shiny Package

artículo científico publicado en 2015

Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.

artículo científico publicado en 2016

Nuances to precision dosing strategies of targeted cancer medicines

artículo científico publicado en 2020

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil

artículo científico publicado en 2016

Patient-reported outcomes as a prognostic marker of survival in patients with advanced non-small cell lung cancer treated with immunotherapy: PROs as a prognostic marker for immunotherapies

artículo científico publicado en 2020

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

artículo científico publicado en 2018

Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data

artículo científico publicado en 2017

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

artículo científico publicado en 2017

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

artículo científico publicado en 2019

Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine

artículo científico publicado en 2019

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data

scientific article published on 01 May 2019

Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.

artículo científico publicado en 2016

Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS

scientific article published on 04 February 2011

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma

scientific article published on 30 November 2019

Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?

artículo científico publicado en 2015

Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC

artículo científico publicado en 2019

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

artículo científico publicado en 2018

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy

scientific article published on 31 July 2020

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

artículo científico publicado en 2020

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.

artículo científico publicado en 2015

Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.

artículo científico publicado en 2016

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.

artículo científico publicado en 2014

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology

scientific article published on 11 January 2019

Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate

artículo científico publicado en 2019

Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma

scientific article published on 14 August 2019

Lista de obras de Ashley M. Hopkins

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift

Author's Reply

Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide

Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability

Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data

Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity

Individualization of leflunomide dosing in rheumatoid arthritis patients

Interactive Pharmacometric Applications Using R and the Shiny Package

Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.

Nuances to precision dosing strategies of targeted cancer medicines

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil

Patient-reported outcomes as a prognostic marker of survival in patients with advanced non-small cell lung cancer treated with immunotherapy: PROs as a prognostic marker for immunotherapies

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data

Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.

Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma

Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?

Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.

Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology

Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate

Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma